Zoetis
Depo moderin depo-medrone 40 mg/ml suspension for injection for cats, dogs and horses 5 ml

For the treatment of inflammatory, allergic and musculoskeletal conditions in cats, dogs and horses

This drug is unauthorized in certain countries
Prescription required* (Exceptions apply)

Depo-Medrone 40 mg/ml is a suspension for injection for the treatment of inflammatory, allergic and musculoskeletal conditions in cats, dogs and horses.

Each ml of Depo-Medrone 40 mg/ml contains:

Active substances

  • Methylprednisolone acetate 40.0 mg

Excipients:

  • Myristyl-gamma-picolinium chloride 0.2 mg
  • Polyethylene glycol
  • Sodium chloride
  • Sodium hydroxide
  • Hydrochloric acid
  • Water for injection

Depo-Medrone 40 mg/ml is indicated:

Cats, dogs and horses:

  • For the treatment of, or as part of a therapeutic regime for, inflammatory and allergic conditions in dogs and cats such as allergic or non-specific inflammatory dermal conditions, musculo-skeletal conditions, ocular/otic inflammatory conditions and other inflammatory/allergic conditions that are likely to respond to corticosteroid therapy e.g. autoimmune disorders.
  • For the treatment of, or as part of a therapeutic regime for, musculoskeletal conditions in horses.

Not to be given intravenously. The technique of aspiration should be employed, as appropriate, to avoid intravascular administration.

Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contra-indicated in the presence of acute infectious conditions.

Do not mix with any other product for injection at the same site.

Systemic corticosteroid therapy is generally contra-indicated in patients with arrested tuberculosis, peptic ulcer, renal disease, diabetes mellitus and Cushing's syndrome.

The product is contra-indicated for the treatment of laminitis in horses.

Depo-Medrol 40 mg/ml posology:

The dosage needed may vary according to individual clinical circumstances such as the severity of the condition to be treated, size of animal, and clinical response.

The following dosage recommendations are therefore initial guidelines and may need slight alteration in the light of individual response. An insulin type syringe should be used to measure and administer volumes of less than 1ml.

  • Local: Aseptic precautions are important.

    • Horses: The average initial dose for a large synovial space is 120 mg (3ml). Smaller spaces will require a correspondingly lesser dose. The intratendinous dose ranges from 80-400 mg (2-10 ml) depending on the size of the tendon.
    • Dogs: The average initial dose for a large synovial space is 20 mg (0.5 ml). Smaller spaces will require a correspondingly lesser dosage.

    • Procedure for intrasynovial injection: the anatomy of the area to be injected should be reviewed in order to ensure that the product is properly placed and that large blood vessels and nerves are avoided. The injection site is located where the synovial cavity is most superficial. The area is prepared for aseptic injection by shaving and disinfection. If there is an excess of synovia and more than 1 ml of the product is to be injected, it is advisable to aspirate a volume of fluid comparable to that which is to be injected. With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the proper amount of the product to be injected. In some animals, a transient pain or synovial flare may be elicited immediately upon injection and may last for up to two to three days. After injection, the structure may be moved gently a few times to aid mixing of the synovial fluid and the product. The site may be covered with a small sterile dressing.

    • Following injection, relief from clinical signs may be experienced within 12-24 hours and be sustained for a variable period but averages three to four weeks, with a range of one to more than five weeks. The continued or prolonged use of the product is discouraged.
  • Intramuscular:
    • Horses: The usual intramuscular dose for horses is 200 mg (5 ml).
    • Dogs and cats: The usual intramuscular dose for dogs and cats is 1-2 mg/kg. Injections may be repeated in accordance with the severity of the condition and clinical response. Relief from clinical signs is usually sustained for up to three weeks but may range from one to more than four weeks.
    • For maintenance therapy in chronic conditions, initial doses should be gradually reduced until the smallest effective dose is established.

Depo-Medrone 40 mg/ml is a suspension for injection for the treatment of inflammatory, allergic and musculoskeletal conditions in cats, dogs and horses.

Each ml of Depo-Medrone 40 mg/ml contains:

Active substances

  • Methylprednisolone acetate 40.0 mg

Excipients:

  • Myristyl-gamma-picolinium chloride 0.2 mg
  • Polyethylene glycol
  • Sodium chloride
  • Sodium hydroxide
  • Hydrochloric acid
  • Water for injection

Depo-Medrone 40 mg/ml is indicated:

Cats, dogs and horses:

  • For the treatment of, or as part of a therapeutic regime for, inflammatory and allergic conditions in dogs and cats such as allergic or non-specific inflammatory dermal conditions, musculo-skeletal conditions, ocular/otic inflammatory conditions and other inflammatory/allergic conditions that are likely to respond to corticosteroid therapy e.g. autoimmune disorders.
  • For the treatment of, or as part of a therapeutic regime for, musculoskeletal conditions in horses.

Not to be given intravenously. The technique of aspiration should be employed, as appropriate, to avoid intravascular administration.

Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contra-indicated in the presence of acute infectious conditions.

Do not mix with any other product for injection at the same site.

Systemic corticosteroid therapy is generally contra-indicated in patients with arrested tuberculosis, peptic ulcer, renal disease, diabetes mellitus and Cushing's syndrome.

The product is contra-indicated for the treatment of laminitis in horses.

Depo-Medrol 40 mg/ml posology:

The dosage needed may vary according to individual clinical circumstances such as the severity of the condition to be treated, size of animal, and clinical response.

The following dosage recommendations are therefore initial guidelines and may need slight alteration in the light of individual response. An insulin type syringe should be used to measure and administer volumes of less than 1ml.

  • Local: Aseptic precautions are important.

    • Horses: The average initial dose for a large synovial space is 120 mg (3ml). Smaller spaces will require a correspondingly lesser dose. The intratendinous dose ranges from 80-400 mg (2-10 ml) depending on the size of the tendon.
    • Dogs: The average initial dose for a large synovial space is 20 mg (0.5 ml). Smaller spaces will require a correspondingly lesser dosage.

    • Procedure for intrasynovial injection: the anatomy of the area to be injected should be reviewed in order to ensure that the product is properly placed and that large blood vessels and nerves are avoided. The injection site is located where the synovial cavity is most superficial. The area is prepared for aseptic injection by shaving and disinfection. If there is an excess of synovia and more than 1 ml of the product is to be injected, it is advisable to aspirate a volume of fluid comparable to that which is to be injected. With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the proper amount of the product to be injected. In some animals, a transient pain or synovial flare may be elicited immediately upon injection and may last for up to two to three days. After injection, the structure may be moved gently a few times to aid mixing of the synovial fluid and the product. The site may be covered with a small sterile dressing.

    • Following injection, relief from clinical signs may be experienced within 12-24 hours and be sustained for a variable period but averages three to four weeks, with a range of one to more than five weeks. The continued or prolonged use of the product is discouraged.
  • Intramuscular:
    • Horses: The usual intramuscular dose for horses is 200 mg (5 ml).
    • Dogs and cats: The usual intramuscular dose for dogs and cats is 1-2 mg/kg. Injections may be repeated in accordance with the severity of the condition and clinical response. Relief from clinical signs is usually sustained for up to three weeks but may range from one to more than four weeks.
    • For maintenance therapy in chronic conditions, initial doses should be gradually reduced until the smallest effective dose is established.
18.00
Order within 5h 18m 21s (before 12AM)
And receive your order
on Tuesday 22 October
AIR FREIGHT

Customers who buy this product, usually buy: